Literature DB >> 24563420

Contrast-enhanced ultrasound (CEUS) for the evaluation of focal liver lesions - a prospective multicenter study of its usefulness in clinical practice.

I Sporea1, R Badea2, A Popescu1, Z Spârchez2, R L Sirli1, M Dănilă1, L Săndulescu3, S Bota1, D P Calescu4, D Nedelcu5, C Brisc6, L Ciobâca7, L Gheorghe8, M Socaciu2, A Martie1, S Ioaniţescu9, A Tamas10, C T Streba3, M Iordache7, I Simionov8, M Jinga7, A Anghel7, C Cijevschi Prelipcean11, C Mihai11, S M Stanciu7, D Stoicescu7, E Dumitru12, C Pietrareanu8, D Bartos13, R Manzat Saplacan14, I Pârvulescu8, R Vădan8, G Smira8, L Tuţă12, A Săftoiu3.   

Abstract

PURPOSE: To assess the value of contrast-enhanced ultrasound (CEUS) for differentiating malignant from benign focal liver lesions (FLLs) and for diagnosing different FLL types.
MATERIAL AND METHODS: CEUS performed in 14 Romanian centers was prospectively collected between February 2011 and June 2012. The inclusion criteria were: age > 18 years; patients diagnosed with 1 - 3 de novo FLLs on B-mode ultrasound; reference method (computed tomography (CT), magnetic resonance imaging (MRI) or biopsy) available; patient's informed consent. FLL lesions were characterized during CEUS according to the European Federation of Societies for Ultrasound in Medicine and Biology guidelines. For statistical analysis, indeterminate FLLs at CEUS were rated as false classifications.
RESULTS: A total number of 536 cases were included in the final analysis, 344 malignant lesions (64.2 %) and 192 benign lesions (35.8 %). The reference method was: CT/MRI - 379 cases (70.7 %), pathological exam - 150 cases (27.9 %) and aspiration of liver abscesses - 7 cases (1.4 %). CEUS was conclusive in 89.3 % and inconclusive in 10.7 % of cases. To differentiate between malignant and benign FLLs, CEUS had 85.7 % sensitivity, 85.9 % specificity, 91.6 % positive predictive value, 77.1 % negative predictive value and 85.8 % accuracy. The CEUS accuracy for differentiation between malignant and benign liver lesions was similar in tumors with diameter ≤ 2 cm and those with diameter > 2 cm.
CONCLUSION: CEUS represents a useful method in clinical practice for differentiating between malignant and benign FLLs detected on standard ultrasonography, and the results of this study are in concordance with previous multicenter studies: DEGUM (Germany) and STIC (France). © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24563420     DOI: 10.1055/s-0033-1355728

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  24 in total

1.  Application of real-time three-dimensional contrast-enhanced ultrasound using SonoVue for the evaluation of focal liver lesions: a prospective single-center study.

Authors:  Ying Lu; Baoxian Liu; Yanling Zheng; Jia Luo; Xiaoer Zhang; Guangliang Huang; Xiaohua Xie; Jieyi Ye; Wei Wang; Xusheng Liu; Xiaoyan Xie
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 2.  Contrast-enhanced ultrasound in liver cancer.

Authors:  Simona Leoni; Ilaria Serio; Anna Pecorelli; Sara Marinelli; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2015-01-12

Review 3.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

Review 4.  Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis.

Authors:  Menglin Wu; Liang Li; Jiahui Wang; Yanyan Zhang; Qi Guo; Xue Li; Xuening Zhang
Journal:  Eur Radiol       Date:  2017-11-30       Impact factor: 5.315

5.  Contrast Enhanced Ultrasound in CT-undetermined Focal Liver Lesions.

Authors:  S W Sandrose; S Karstrup; O Gerke; S Rafaelsen
Journal:  Ultrasound Int Open       Date:  2016-11

6.  Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Bang-Bin Chen; Takamichi Murakami; Tiffany Ting-Fang Shih; Michiie Sakamoto; Osamu Matsui; Byung-Ihn Choi; Myeong-Jin Kim; Jeong Min Lee; Ren-Jie Yang; Meng-Su Zeng; Ran-Chou Chen; Ja-Der Liang
Journal:  Liver Cancer       Date:  2015-10-15       Impact factor: 11.740

7.  Contrast enhancement ultrasound application in focal liver lesions characterization: a retrospective study about guidelines application (SOCEUS-CEUS survey).

Authors:  Mirko D'Onofrio; Laura Romanini; Carla Serra; Fabrizio Magnolfi; Michele Bertolotto; Emilio Quaia; Gino Puntel; Alessandro Colleoni; Erica Fiorini; Cristina Cenci; Elena Santi; Valentina Ciaravino; Francesco Laffranchi; Orlando Catalano; Vito Cantisani; Fabrizio Calliada; Lorenzo Derchi
Journal:  J Ultrasound       Date:  2015-11-02

8.  Contrast enhanced ultrasound guided biopsies of liver lesions not visualized on standard B-mode ultrasound-preliminary experience.

Authors:  Sasan Partovi; Ziang Lu; Rivka Kessner; Alice Yu; Yasmine Ahmed; Indravadan J Patel; Dean A Nakamoto; Nami Azar
Journal:  J Gastrointest Oncol       Date:  2017-12

Review 9.  [Contrast-enhanced ultrasound (CEUS) and image fusion for procedures of liver interventions].

Authors:  E M Jung; D A Clevert
Journal:  Radiologe       Date:  2018-06       Impact factor: 0.635

10.  The value of contrast-enhanced ultrasound in predicting postoperative recurrence of hepatocellular carcinoma: A protocol for systematic review and meta-analysis.

Authors:  Jieying Fu; Jia Tang; Huan Luo; Wencui Wu
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.